Holen Sie sich die Stockscreener-App
1.98
2.06%
0.04
Handel nachbörslich:
1.98
Schlusskurs vom Vortag:
$1.94
Offen:
$1.91
24-Stunden-Volumen:
555.86K
Relative Volume:
0.34
Marktkapitalisierung:
$62.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.00M
KGV:
-0.7122
EPS:
-2.78
Netto-Cashflow:
$-55.26M
1W Leistung:
+1.02%
1M Leistung:
-18.85%
6M Leistung:
+38.46%
1J Leistung:
-64.39%
1-Tages-Spanne:
$1.91
$2.0094
1-Wochen-Bereich:
$1.91
$2.19
52-Wochen-Spanne:
$1.05
$8.00
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Firmenname
Acrivon Therapeutics Inc
Sektor
Branche
Telefon
617-207-8979
Adresse
480 ARSENAL WAY, SUITE 100, WATERTOWN
Vergleichen Sie ACRV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.98 | 61.22M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-31 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-12-15 | Fortgesetzt | Jefferies | Buy |
| 2023-10-05 | Eingeleitet | Maxim Group | Buy |
| 2023-06-02 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-04-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-12-12 | Eingeleitet | Jefferies | Buy |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
CEO Change: Does Vinci Partners Investments Ltd stock benefit from AI growthMarket Volume Report & Advanced Technical Signal Analysis - baoquankhu1.vn
Acrivon to present ACR-368 endometrial cancer data at ESGO congress - Investing.com Nigeria
Endometrial cancer trial ACR-368 to be featured at European oncology event - Stock Titan
Acrivon Therapeutics Announces Late-Breaking Oral - GlobeNewswire
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress - Yahoo Finance
ACRV Stock Price, Forecast & Analysis | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - Chartmill
Penny Stocks To Watch In January 2026 - Yahoo Finance
Insider Spends US$82k Buying More Shares In Acrivon Therapeutics - simplywall.st
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares - Yahoo Finance
Price Action: Can Acrivon Therapeutics Inc ride the EV waveDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Acrivon Therapeutics CEO Blume-Jensen buys $82k in shares By Investing.com - Investing.com Canada
Acrivon Therapeutics CEO Blume-Jensen buys $82k in shares - Investing.com
Top Brass Doubles Down on Acrivon With Bold Insider Buying Spree - TipRanks
Volume Report: Is BMLPRJs ROE strong enoughEarnings Risk Report & Risk Managed Investment Signals - baoquankhu1.vn
Insider Buying: Adam Levy Acquires Shares of Acrivon Therapeutics Inc (ACRV) - GuruFocus
Acrivon Therapeutics (NASDAQ:ACRV) CFO Adam Levy Acquires 8,832 Shares - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) CEO Peter Blume-Jensen Purchases 49,000 Shares - MarketBeat
Aug Decliners: Can Acrivon Therapeutics Inc ride the EV waveCEO Change & Smart Allocation Stock Tips - baoquankhu1.vn
Top Acrivon Executive Makes Bold Insider Move That Signals Growing Confidence - TipRanks
Acrivon Therapeutics COO Devroe buys $17k in shares By Investing.com - Investing.com Nigeria
Insider Buying: Eric Devroe Acquires 10,000 Shares of Acrivon Th - GuruFocus
Acrivon Therapeutics COO Devroe buys $17k in shares - Investing.com
Acrivon Therapeutics (NASDAQ:ACRV) COO Purchases $17,200.00 in Stock - MarketBeat
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction - Intellectia AI
Movement Recap: What risks investors should watch in Acrivon Therapeutics Inc stockMarket Performance Summary & Safe Entry Momentum Stock Tips - Bộ Nội Vụ
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Growth Value: Can Acrivon Therapeutics Inc expand into new marketsJuly 2025 Momentum & Entry Point Confirmation Signals - baoquankhu1.vn
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen - MarketBeat
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data By Investing.com - Investing.com South Africa
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com Australia
Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com - Investing.com Nigeria
How Acrivon Therapeutics Inc. stock compares to market leadersM&A Rumor & Long-Term Safe Investment Plans - Улправда
What is the fair value of Acrivon Therapeutics Inc. stock nowJuly 2025 Sector Moves & Verified Chart Pattern Signals - Улправда
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm
Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls - Sahm
Why Acrivon Therapeutics Inc. stock could rally in 2025Treasury Yields & Community Consensus Picks - Улправда
Treasury Yields: Can Acrivon Therapeutics Inc. stock resist market sell offsWeekly Trade Summary & High Accuracy Investment Entry Signals - Улправда
Why Acrivon Therapeutics Inc. stock remains a top recommendationInflation Watch & Fast Moving Market Watchlists - Улправда
Why retail investors pile into Acrivon Therapeutics Inc. stockSwing Trade & Long-Term Growth Stock Strategies - Улправда
Small-Cap Acrivon Showcases Tumor Reduction and Clinical Advancement in Major Trials, Shares Decline - Bitget
Acrivon Therapeutics Inc.: Rise or Retreat? - StocksToTrade
Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data - Nasdaq
Aug Gainers: What is the fair value of Acrivon Therapeutics Inc. stock now2025 Key Lessons & High Accuracy Trade Signal Alerts - Улправда
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating - TipRanks
Exit Recap: Why retail investors pile into Acrivon Therapeutics Inc. stockOptions Play & Safe Entry Point Alerts - ulpravda.ru
Why Is Acrivon Therapeutics Stock Falling Today?Acrivon Therapeutics (NASDAQ:ACRV) - Benzinga
Finanzdaten der Acrivon Therapeutics Inc-Aktie (ACRV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):